Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are 18 years of age or older at the time they sign the consent form, of any sex, and willing to follow the study procedures.
- People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site).
- People who have been diagnosed with non-small cell lung cancer (NSCLC) at a stage that can be surgically removed (clinical stage II to IIIB with specific lymph node involvement), and who have received 3 to 4 rounds of a standard combination treatment — an immune checkpoint drug (PD-1 antibody) together with a platinum-based two-drug chemotherapy — before surgery.
- People whose removed tumor tissue has been assessed and found to have a major response to treatment, meaning less than 10% of the original tumor cells remain.
- People who have had their NSCLC completely removed by surgery, with no cancer left behind and all surgical cut edges clear of cancer cells.
- People whose lung cancer has been confirmed by laboratory testing of tissue or cell samples as either squamous or non-squamous NSCLC.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who only had a small portion of the lung removed (segmental or wedge resection), or who did not have the nearby lymph nodes removed and examined during surgery.
- People who have received cancer treatments after surgery that are not part of this study's plan, such as radiation, chemotherapy, targeted therapy, or other immune therapies (herbal anti-cancer therapies require a 2-week clearance period before joining).
- People who experienced severe immune-related side effects (grade 3 or higher) or serious organ damage during the pre-surgery immunotherapy treatment.
- People who have previously had a bone marrow or organ transplant from another person.
- People who have had, or currently have, inflammation or scarring of the lung tissue (interstitial pneumonitis or lung disease) that has required treatment with steroid medications.
- People with high blood pressure that is not well controlled (resting blood pressure at or above 150/90 mmHg), noting that blood pressure medications must have been at a stable dose for at least 7 days before starting the study drug.
- People who have been diagnosed with another cancer in the past 5 years that still requires active treatment, except for cancers that the treating doctor considers to be fully cured.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chang Chen, MD, PhD, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
Phone: 19102122052
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year DFS rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.